Aspirin for Uncontrolled Asthma

Uncontrolled Asthma Clinical Trial

— ASTHMIRINE  

Official title:

Aspirin for Uncontrolled Asthma : a Randomized Controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02906761
• Other study ID #: P130954
• Secondary ID: 2016-000739-42
• Status: Completed
• Phase: Phase 3
• Start date: January 15, 2019
• Est. completion date: June 17, 2021

Study information

• Verified date: September 2022
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Asthma is characterized by changes in eicosanoids metabolism, especially high production of bronchoconstrictive cysteinyl leukotrienes (CystLTBs) and leukotriene B4 (LTB4). Recent studies have also demonstrated a relative low production of lipoxin A4, an endogenous lipid mediator resulting from lipo-oxygenase action, distinct from CystLTBs, with anti-inflammatory properties, in bronchial epithelial cells and lung macrophages of severe asthma patients, leading to imbalance between pro-resolving and pro-inflammatory eicosanoids production in airways. Such data suggest that aspirin, that induces lipoxins production, could restore lipoxins deficit in severe asthma. Interest for aspirin is also supported by data obtained in asthma patients with aspirin intolerance (Aspirin induced asthma, AIA) : in this particular group of patients, aspirin treatment significantly improves nasal symptoms, quality of life, asthma and rhinitis scores, and reduces need for hospitalizations, nasal surgery and oral steroids use. Potential effect of aspirin in patients with uncontrolled asthma without aspirin intolerance, who presented changes in arachidonic acid pathway close to those observed in AIA, is not established.

The aim of the study is to assess whether long term aspirin treatment could improve asthma control, compared to placebo, in patients with uncontrolled disease and nasal polyposis, whatever their aspirin tolerance level.

Description:

Asthma concerns about 7% of the French adult population. About 10% of them have uncontrolled disease, despite high doses of inhaled steroids combined with long acting beta 2 agonists and adequate management of aggravating factors. They account for considerable asthma morbidity, mortality and costs. New treatments are needed for these patients.

Asthma is characterized by changes in eicosanoids metabolism, especially high production of bronchoconstrictive cysteinyl leukotrienes and LTB4. Recent studies have also demonstrated a relative low production of lipoxin A4, an endogenous lipid mediator resulting from lipo-oxygenase action, distinct from CystLTBs, with anti-inflammatory properties, in bronchial epithelial cells and lung macrophages of severe asthma patients, leading to imbalance between pro-resolving and pro-inflammatory eicosanoids production in airways. Such data suggest that aspirin, that induces lipoxins production, could restore lipoxins deficit in severe asthma, as demonstrated in other models.

Interest for aspirin is also supported by data obtained in asthma patients with aspirin intolerance (Aspirin induced asthma, AIA), who are characterized by a severe difficult-to-treat respiratory disease frequently associated with nasal polyposis, overproduction of leukotrienes and increased expression of leukotriene receptors. In this particular group of patients, aspirin treatment significantly improves nasal symptoms, quality of life, asthma and rhinitis scores, and reduces need for hospitalizations and nasal surgery. A reduction in oral steroids use was observed in most series. In this group of patients, aspirin also induced a decrease in interleukin 4 (IL-4) and Matrix metallopeptidase 9 (MMP-9) levels in sputum in asthma patients thus providing another explanation for anti inflammatory effect of aspirin in asthma. Patients treated with higher doses of aspirin (650 mg BID) had more favorable courses than those treated with lower doses.Aspirin desensitization is considered as a cost-effective therapeutic intervention in patients with moderate-to-severe AIA However, some of these studies, coming mostly from the same team, can be criticized for methodological reasons, low evidence, small series, and weak asthma characterization.

Potential effect of aspirin in patients with uncontrolled asthma without aspirin intolerance, who presented changes in arachidonic acid pathway close to those observed in AIA, is not established. Because similar changes in eicosanoid metabolism are described in nasal polyps mucosa, a pathology frequently associated with asthma, we hypothesize that patients with nasal polyps and asthma could be a specific target for aspirin treatment.

Aspirin is a cheap treatment, compared with biotherapies developed for severe asthma.

Hypothesis The investigators propose to compare the effect aspirin (600 mg twice daily) versus placebo, given during six months, on asthma control in patients with uncontrolled asthma and nasal polyposis, whatever their aspirin level of tolerance, in a randomized, double blind, placebo-controlled trial.

Study objectives Primary objective To assess whether long term aspirin treatment could improve asthma control, compared to placebo, in patients with uncontrolled disease and nasal polyposis, whatever their aspirin tolerance level.

Secondary objectives

To assess the effect of long term aspirin treatment compared to placebo, in patients with uncontrolled disease and nasal polyposis, on the following criteria:

• lung function

• number of exacerbations

• time to the first exacerbation

• oral and inhaled steroid use and doses

• Nasal symptoms

• Nasal sinus symptoms severity

• quality of life

• Lipoxin A4, cysteinyl leukotrienes (cystLT) and LTB4 levels in sputum

• Reactions during oral aspirin challenge

• Gastro-intestinal and other bleedings

Study design This is a multicentric, randomized, placebo-controlled, double-blinded phase III clinical trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: June 17, 2021
• Est. primary completion date: June 17, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age : 18 to 75 years old

• Patients receiving inhaled steroids (>1000 µg/d beclomethasone or equivalent) combined with long acting beta agonist at a stable dose for at least 1 month and montelukast for at least 2 weeks.

• Patients receiving Proton Pump Inhibitors for at least 2 weeks

• Uncontrolled asthma defined by an ACQ 6 score=1.5 at baseline

• Recurrent chronic rhinosinusitis with nasal polyposis diagnosed by nasal endoscopy by an otorhinolaryngologist

• Evidence of reversibility of airway obstruction defined as an increase of FEV1 of 12% or greater and at least 200 ml after Short Acting Beta Agonists (SABA) administration OR after oral corticoid test or an increase of CVF of 12% or greater and at least 200 ml after Short Acting Beta Agonists (SABA) administration or after oral corticoid test OR a variation in FEV1 of more than 200 ml and 12% between 2 follow-up visits OR variation of the Peak Expiratory Flow Rate (PEF) with a delta PEF over the day / average PEF over 2 weeks > 10% OR a positive methacholine bronchial challenge test: decrease in FEV1 by more than 20% for a dose < 1600 µg documented once during medical history

• FEV1>1.5l and 60% of predicted value at inclusion

• Never smoked or non-smoker for at least 6 months, with a smoking history of no more than 10 pack-years

• Written informed consent

• Efficient contraception, other than an intrauterine device (IUD), for women of reproductive age

Exclusion Criteria:

• Evidence of another clinically significant, active pulmonary disorder (bronchiectasis, chronic obstructive pulmonary disease (COPD), …) that could influence asthma control evaluation

• Patient treated regularly with aspirin or NSAID for another pathology

• Hypersensitive response to lansoprazole

• treatment by nelfinavir or other HIV protease inhibitors for which absorption depends on gastric pH (atazanavir...)

• Asthma exacerbation within the 4 weeks prior to inclusion (as defined by an oral corticotherapy for more than 48h or a 2-fold increase of oral corticoid intake )

• Pregnancy or breast feeding

• Recent myocardial infarction within the 6 months prior to inclusion

• immunodeficiency

• Patients receiving bet-blockers

• Contra-indication for aspirin : history of gastro-intestinal or cerebral bleeding, active gastric or duodenal ulcer, major surgery within the 4 weeks prior to inclusion, treatment with methotrexate, probenecid, selective serotonin re-uptake inhibitor, diuretic, angiotensin-converting-enzyme inhibitor, angiotensin receptor inhibitor or anti-platelet drug, ,any hemorrhagic risk according to the investigator, heart, liver or kidney failure, hyperuricemia, phenylketonuria.

• Major surgery planned during the 6 month study period

• under security or legal protection measures

• patient intolerant to lactose or other excipient

• Patient with intra-uterine device

• patient who has not given written consent

• Non affiliation to a social security scheme (beneficiary or assignee)

Secondary exclusion criteria :

-Patients who will require epinephrine injection or transfer to ICU or patients who do not reach the maximum dose of 600mg during aspirin challenge-desensitization will stop the study and not be randomized

Related Conditions & MeSH terms

• Asthma
• Uncontrolled Asthma

Intervention

Drug:
• Aspirin
Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
• Placebo
Placebo (2 tablets) twice daily for 6 months

Locations

Country	Name	City	State
France	Service de pneumologie - CHU Besançon	Besançon
France	Service de Pneumologie - Hôpital François Mitterrand - CHU Dijon	Dijon
France	Service de Pneumologie - Hôpital Bicêtre	Le Kremlin Bicetre
France	Service de pneumologie - Hôpital Calmette - CHRU Lille	Lille
France	Service de Pneumologie - La Croix Rousse	Lyon
France	CIC - Hôpital Bichat	Paris
France	Service de pneumologie - Hôpital Charles Nicolle - CHU Rouen	Rouen
France	Service de pneumologie - Nouvel Hopital Civil - CHU strasbourg	Strasbourg
France	Service de pneumologie - Hôpital Larrey	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in asthma Control Questionnaire (ACQ 6) score between baseline and 6 months	Patients will fill in ACQ6 at each visit (day 0, 1 month, 3 months and 6 months)	6 months
Secondary	Forced expired volume in 1 second (FEV1) variation between baseline and 6 months	A spirometry will be done at each visit (day 0, 1 month, 3 months and 6 months)	6 months
Secondary	number of exacerbations	The number of exacerbations will be assessed at each visit (day 0, 1 month, 3 months and 6 months)	6 months
Secondary	Time to first exacerbation	Time to first exacerbation will be assessed at each visit (day 0, 1 month, 3 months and 6 months)	6 months
Secondary	number of hospitalization	number of hospitalization	6 months
Secondary	oral steroid use	oral steroid use	6 months
Secondary	inhaled steroid doses	inhaled steroid doses	6 months
Secondary	nasal sinus symptoms severity at baseline and 6 months	Patients will fill in Sino-Nasal Outcome Test 16 (SNOT 16) questionnaire at each visit .The SNOT-16 is a quality of life, self-administered questionnaire comprising 16 questions.; Responses are scored as: 0 = no bother, 1 = mild or minor bother, 2 = moderate bother, 3 = severe bother. Patients are also asked to check to five items which are most important to them personally. Scores range (sum of each question) from 0 (no functional bother) to 48 (maximal functional bother) (day 0, 1 months, 3 months and 6 months)	6 months
Secondary	measure of quality of life: AQLQ	Patients will fill in Asthma Quality of Life Questionnaire (AQLQ) at each visit (day 0, 1 months, 3 months and 6 months). There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). The activity domain contains 5 'patient-specific' questions. This allows patients to select 5 activities in which they are most limited and these activities will be assessed at each follow-up. Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains.	6 months
Secondary	Lipoxin A4 (LXA4) levels in sputum	LXA4 levels at day 0 and 6 months will be measured by ELISA kit	6 months
Secondary	Cyst-LT levels in sputum	Cyst-LT levels at day 0 and 6 months will be measured by ELISA kit	6 months
Secondary	LTB4 levels in sputum	LTB4 levels at day 0 and 6 months will be measured by ELISA kit	6 months
Secondary	Reactions during oral aspirin challenge test	Occurrence of intolerance symptom : angioedema, bronchospasm, rhinitis, urticaria...	3 to 4 days
Secondary	Digestive tolerance during treatment	Medical examination, patient interview	6 months
Secondary	gastro-intestinal bleedings during treatment	Occurence by bleedings during treatment, patient interview	6 months